### CARC-5

**External request:** Submission from Novartis Oncology to add everolimus as an option for patients with advanced carcinoid tumors.

- **Panel Discussion:** Based on the noted reference, the panel consensus was to add everolimus as an option for patients with advanced carcinoid tumors with a category 3 designation.

- **References:**
  

- **Vote:**
  - YES: 14
  - NO: 2
  - ABSTAIN: 1

### CARC-5 and PancNET-5

**Internal request:** Panel discussion comment to reorganize the algorithm for the management of locoregional unresectable disease and/or distant metastases.

- **Panel Discussion:** Based on panel consensus and the reorganization of the recommendations based on disease status rather than metastatic site, bisphosphonates (pamidronate disodium, zoledronic acid) in combination with radiation therapy were removed from the guideline.

- **Vote:**
  - YES: 17
  - NO: 0
  - ABSTAIN: 0

### PancNET-1

**Internal request:** Panel discussion comment for the inclusion of octreotide acetate for the management of primary nonmetastatic gastrinoma.

- **Panel Discussion:** Based on panel consensus and supported by the noted references, octreotide acetate was added as an option for the management of primary nonmetastatic gastrinoma.

- **References:**
  


- **Vote:**
  - YES: 17
  - NO: 0
  - ABSTAIN: 0
| PancNET-2 | Internal request: Panel discussion comment to remove octreotide acetate for the management of primary nonmetastatic insulinoma. | Based on panel consensus and supported by the noted reference, octreotide acetate was removed as a management option for primary nonmetastatic insulinoma. | Stehouwer CD, Lems WF, Fischer HR, et al. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh) 1989;121:34-40. Available at: [http://www.ncbi.nlm.nih.gov/pubmed/2545062](http://www.ncbi.nlm.nih.gov/pubmed/2545062) | 17 | 0 | 0 |